Outcomes for COPD pharmacological trials: from lung function to biomarkers

M. Cazzola*, W. MacNee, F.J. Martinez, K.F. Rabe, L.G. Franciosi, P.J. Barnes, V. Brusasco, P.S. Burge, P.M. Calverley, B.R. Celli, P.W. Jones, D.A. Mahler, B. Make, M. Miravitlles, C.P. Page, P. Palange, D. Parr, M. Pistolesi, S.I. Rennard, M.P.M.H. Rutten-van MölkenR. Stockley, S.D. Sullivan, J.A. Wedzicha, E.F. Wouters

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review


    The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations.
    Original languageEnglish
    Pages (from-to)416-69
    JournalEuropean Respiratory Journal
    Issue number2
    Publication statusPublished - 1 Jan 2008


    Dive into the research topics of 'Outcomes for COPD pharmacological trials: from lung function to biomarkers'. Together they form a unique fingerprint.

    Cite this